Latent tuberculosis infection: Difference between revisions

From IDWiki
No edit summary
No edit summary
Line 1: Line 1:
  +
* Prior exposure to TB leading to persistent latent tuberculosis, usually contained within lung ganulomas
== Definition ==
 
 
* Prior exposure to TB
 
 
* Goal is to identify those who are at increased risk of developing active TB and would benefit from treatment
 
* Goal is to identify those who are at increased risk of developing active TB and would benefit from treatment
   
Line 12: Line 10:
 
** Preferred for those who have received BCG after infancy
 
** Preferred for those who have received BCG after infancy
   
== Positive TBST ==
+
=== Positive TBST ===
   
 
# Is it truly positive?
 
# Is it truly positive?
Line 27: Line 25:
 
#* INH 300 daily x9 mo with pyridoxine
 
#* INH 300 daily x9 mo with pyridoxine
 
#* baseline liver enzymes and vision testing
 
#* baseline liver enzymes and vision testing
  +
  +
== Management ==
  +
  +
* Standard regimen (9INH):
  +
** Nine months of isoniazid with daily vitamin B6
  +
* Alternative shorter courses:
  +
** 6INH
  +
** 3-4INH/RMP
  +
** 4RIF, maybe
   
 
== Further Reading ==
 
== Further Reading ==

Revision as of 13:36, 18 September 2019

  • Prior exposure to TB leading to persistent latent tuberculosis, usually contained within lung ganulomas
  • Goal is to identify those who are at increased risk of developing active TB and would benefit from treatment

Investigations

  • Tuberculin skin test (TBST)
    • Sens 90%, Spec >95
  • Interferon-gamma release assay (IGRA)
    • Sn 95%, Sp >95%
    • Preferred for those who have received BCG after infancy

Positive TBST

  1. Is it truly positive?
    • Consider IGRA
    • BCG vaccine can be considered a cause of false positive when
      • vaccine given after 12 months of age, and
      • patient has no risk factors, and
      • either Canadian-born non-Aboriginal, or not from endemic country
  2. Rule out active TB
    • signs/symptoms
    • CXR or CT chest
    • Sputum x3 if coughing or cavitary lesions
  3. Evaluate risk of reactivation treatment
    • INH 300 daily x9 mo with pyridoxine
    • baseline liver enzymes and vision testing

Management

  • Standard regimen (9INH):
    • Nine months of isoniazid with daily vitamin B6
  • Alternative shorter courses:
    • 6INH
    • 3-4INH/RMP
    • 4RIF, maybe

Further Reading

Tools